Abstract
Specific coagulation factor inhibitors, most notably to coagulation factor VIII, can develop in patients with hemophilia after exposure to replacement factor or as an acquired (autoimmune) event. Such inhibitors can be detected by a combination of prolonged coagulation screening tests, such as the activated partial thromboplastin time, plus a non-correcting mixing test. Non-correction may only be evident, or else may be extenuated, with incubation at 37 °C. The Bethesda assay for quantitation of inhibitor strength is based on a combination of mixing tests followed by specific factor assays.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Green D, Lechner K (1981) A survey of 215 non-haemophiliac patients with inhibitors to factor VIII. Thromb Haemost 45:200–203
Kazmi MA, Pickering W, Smith MP, Holland LJ, Savage GF (1998) Acquired haemophilia A: errors in the diagnosis. Blood Coagul Fibrinolysis 9:623–628
Kershaw G, Jayakodi D, Dunkley S (2009) Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center. Semin Thromb Hemost 35:760–768
Kasper CK, Aledort LM, Counts RB et al (1975) Letter: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34:869–872
Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E (1995) The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 73:247–251
Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I (1998) A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of hemophilia centre directors of Canada. Factor VIII/IX subcommittee of scientific and standardization committee of international society on thrombosis and haemostasis. Thromb Haemost 79:872–875
Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM, Hemophilia Inhibitor Research Study Investigators (2012) Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost 10:1055–1061
Verbruggen B, van Heerde W, Novákovà I, Lillicrap D, Giles A (2002) A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen modification of the Bethesda factor VIII:C inhibitor assay. Thromb Haemost 88:362–864
Kershaw GW, Chen LS, Jayakodi D, Dunkley SM (2013) Validation of 4% albumin as a diluent in the Bethesda assay for FVIII inhibitors. Thromb Res 132:735–741
Kitchen S, McCraw A (2000) Diagnosis of haemophilia and other bleeding disorders: a laboratory manual. World Federation of Hemophilia, Montreal, pp 72–76
Dardikh M, Albert T, Masereeuw R, Oldenburg AJ, Novakova I, Van Heerde WL, Verbruggen B (2012) Low-titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half-life after immune tolerance induction. J Thromb Haemost 10:706–708
Gadarowski JJ Jr, Czapek EE, Ontiveros JD, Pedraza JL (1988) Modification of the Bethesda assay for factor VIII or IX inhibitors to improve efficiency. Acta Haematol 80:134–138
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Kershaw, G. (2017). Detection and Measurement of Factor Inhibitors. In: Favaloro, E., Lippi, G. (eds) Hemostasis and Thrombosis. Methods in Molecular Biology, vol 1646. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7196-1_23
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7196-1_23
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7194-7
Online ISBN: 978-1-4939-7196-1
eBook Packages: Springer Protocols